ASRA Family

migraine h

Comments on Medicare Program, CY 2021 Address Multiple Concerns

Oct 6, 2020


Friday, ASRA submitted comments to the Centers for Medicare and Medicaid Services regarding a number of aspects of two proposed rules.

In a letter to Administrator Seema Verma, MPH, ASRA presented feedback on several issues regarding CMS-1723-P:

  1. Mitigate the steep cut to the conversion factor due to multiple changes in evaluation and management (E/M) payment and related policies;
  2. Translate the increase E/M values to global surgery codes;
  3. Continue coverage and increased payment for telephone only E/M services;
  4. Work with Congress to eliminate originating site requirements and geographic restrictions;
  5. Withdraw policies that inappropriately expand scope of practice of non-physician practitioners;
  6. Work with federal agency partners to remove barriers to electronic prescribing of controlled substances (EPCS);
  7. Delay implementation of MIPS Value Pathways (MVPs); and,
  8. Retain the current (Year 4) MIPS Quality and Cost performance category weights and performance thresholds, in light of COVID-19 pandemic efforts.

In a letter to Administrator Verma regarding CMS-1736-P, ASRA addressed issues regarding:

  1. Delay elimination of the Inpatient Only List (IPO) List, and
  2. Eliminate all prior authorizations under the OPPS, but especially for implanted spinal neurostimulators.
Close Nav